Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 3/20 | 0.36 |
| ▸ | NOS1 | P29475 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | ILK | Q13418 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1911330 | 0.81 | ALDH1A1 (0.42) | ALDH1A1KDM4EGAAMAPK1 | |
| SCHEMBL15506139 | 0.81 | CYP2A6 (0.45) | CYP2A6ALDH1A1KCNH2MAPK1 | |
| SCHEMBL17640942 | 0.80 | KCNH2 (0.42) | ALDH1A1MAPTKCNH2 | |
| SCHEMBL12128097 | 0.79 | KCNH2 (0.43) | ALDH1A1MAPTKCNH2 | |
| SCHEMBL38560 | 0.78 | MAPT (0.54) | ALDH1A1KDM4EMAPTGAARECQL | |
| SCHEMBL5223976 | 0.76 | PLA2G2A (0.54) | ALDH1A1MAPTRECQL | |
| SCHEMBL18923532 | 0.76 | ALDH1A1 (0.36) | ALDH1A1KDM4EMAPTKCNH2EGFR | |
| SCHEMBL39013 | 0.76 | MAPT (0.60) | ALDH1A1MAPTGAARECQL | |
| SCHEMBL5225023 | 0.75 | MAPT (0.48) | ALDH1A1MAPTRECQL | |
| SCHEMBL15720366 | 0.75 | APP (0.37) | ALDH1A1KDM4EMAPTRECQLEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920054-B2 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170233390-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233390-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | RORC, RORB, RORA | CYP2A6 1068/4885ALDH1A1 715/4885KDM4E 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.